Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643742 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
A Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 7
- Study locations
NCT05643742 is a Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 120 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (21% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05643742, a Phase 1 study of Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Conditions Studied
Interventions
- BIOLOGICAL CTX112
Study Locations (7)
Kansas
- University of Kansas - Westwood
Missouri
- Washington University - St Louis
Texas
- SCRI - San Antonio
Utah
- University of Utah - Salt Lake City
New South Wales
- Royal Prince Alfred - Camperdown
Victoria
- Alfred Health - Melbourne
Western Australia
- Sir Charles Gairdner Hospital - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2030-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05643742
The ClinicalTrials.gov registry entry for NCT05643742 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (21% lower). The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CTX112 is the first listed.
NCT05643742 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Kansas, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT05643742 about?
NCT05643742 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies". This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
What is the current status of trial NCT05643742?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-03-10. Estimated completion is 2030-02.
What conditions does trial NCT05643742 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT05643742?
The interventions under investigation include: CTX112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05643742?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05643742 being conducted?
This trial has 7 study locations across Kansas, Missouri, Texas, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.